Angiotensin II type 2 receptor agonist Compound 21 attenuates pulmonary inflammation in a model of acute lung injury
Mario Menk, Jan Adriaan Graw, Clarissa von Haefen, Hendrik Steinkraus, Burkhard Lachmann, Claudia D Spies, David Schwaiberger Department of Anesthesiology and Operative Intensive Care Medicine, Charité – University Medicine Berlin, FreieUniversität Berlin, Humboldt-Univ...
Main Authors: | Menk M, Graw JA, von Haefen C, Steinkraus H, Lachmann B, Spies CD, Schwaiberger D |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-05-01
|
Series: | Journal of Inflammation Research |
Subjects: | |
Online Access: | https://www.dovepress.com/angiotensin-ii-type-2-receptor-agonist-compound-21-attenuates-pulmonar-peer-reviewed-article-JIR |
Similar Items
-
Role of P21 in Resistance of Lung Cancer
by: Tian FU, et al.
Published: (2020-07-01) -
Comparison Study of Cyfra 21-1, Carcinoembryonic Antigen and Telomerase Activity between Non Small Cell and Small Cell Lung Cancer Patients
by: Behrang Alani, et al.
Published: (2008-12-01) -
The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury
by: Anandharajan Rathinasabapathy, et al.
Published: (2018-03-01) -
Initiation of LPS-induced pulmonary dysfunction and its recovery occur independent of T cells
by: Eva Verjans, et al.
Published: (2018-11-01) -
TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21–IL-4 pathway in lung adenocarcinoma
by: Shuangtao Zhao, et al.
Published: (2018-04-01)